@article {Masi{\'a}2020.11.16.20230003, author = {Mar Masi{\'a} and Marta Fern{\'a}ndez-Gonz{\'a}lez and Manuel S{\'a}nchez and Mar Carvajal and Jos{\'e} Alberto Garc{\'\i}a and Nieves Gonzalo and Victoria Ortiz de la Tabla and Vanesa Agull{\'o} and Inmaculada Candela and Jorge Guijarro and Jos{\'e} Antonio Guti{\'e}rrez and Carlos de Gregorio and F{\'e}lix Guti{\'e}rrez}, title = {Nasopharyngeal Panbio COVID-19 antigen performed at point-of-care has a high sensitivity in symptomatic and asymptomatic patients with higher risk for transmission and older age}, elocation-id = {2020.11.16.20230003}, year = {2020}, doi = {10.1101/2020.11.16.20230003}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Performance of point-of-care tests in clinical practice remains undetermined. We aimed to evaluate the performance of the nasopharyngeal Panbio COVID-19 antigen Rapid Test Device in real-life conditions in different clinical scenarios.Method Prospective study conducted in three primary care centers (PCC) and an emergency department. The antigen test was performed at point-of-care in nasopharyngeal and nasal swabs, and in saliva. Positive and negative percent agreement (PPA, NPA) were calculated with the RT-PCR assay as reference standard.Results Of 913 patients included, 296 (32.3\%) were asymptomatic and 690 (75.6\%) came from the PCC. Nasopharyngeal swabs were collected from 913, nasal swabs from 659, and saliva from 611 patients. RT-PCR was positive in 196 (21.5\%) nasopharyngeal samples (NPS). Overall PPA (95\% CI) in NPS was 60.5\% (53.3-67.4), and it was lower in nasal swabs (44.7\%) and saliva (23.1\%). Test performance in NPS was largely dependent on the cycle threshold (Ct) in RT-PCR, with PPA\>90\% for Ct<=25 and >=80\% for Ct\<30. In symptomatic patients, the PPA was 95\% for Ct<=25; >=85\% for Ct\<30, and 89\% for the symptom triad of fever, cough and malaise. Performance was also dependent on age, with PPA of 100\% in symptomatic patients \>50 years with Ct\<25. In asymptomatic patients, the PPA was 86\% for Ct\<25. In all cases, NPA was 100\%.Conclusion The nasopharyngeal Panbio COVID-19 antigen test performed at point-of-care is highly sensitive in symptomatic patients, particularly with Ct\<30 and older age. The test was useful to identify asymptomatic patients with lower Ct values and therefore with contagious risk.Key points The nasopharyngeal Panbio-COVID-19 antigen test performed in real-life conditions at point-of-care is highly sensitive in symptomatic patients, particularly with Ct\<30 and older age. The test is useful to identify asymptomatic patients with lower Ct values and therefore with contagious risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the RD16/0025/0038 project as a part of the Plan Nacional Research + Development + Innovation (R+D+I) and cofinanced by Instituto de Salud Carlos III - Subdireccion General de Evaluacion y Fondo Europeo de Desarrollo Regional; Instituto de Salud Carlos III (Fondo de Investigaciones Sanitarias [grant number PI16/01740; PI18/01861; CM 19/00160 COV20-00005]).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was given by the Hospital General Universitario de Elche COVID-19 Institutional Advisory BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.}, URL = {https://www.medrxiv.org/content/early/2020/11/17/2020.11.16.20230003}, eprint = {https://www.medrxiv.org/content/early/2020/11/17/2020.11.16.20230003.full.pdf}, journal = {medRxiv} }